N4 Pharma PLC Nuvec resource changes (6494H)
16 Noviembre 2018 - 7:36AM
UK Regulatory
TIDMN4P
RNS Number : 6494H
N4 Pharma PLC
16 November 2018
16 November 2018
N4 Pharma Plc
("N4 Pharma" or the "Company")
Nuvec(R) resource changes
N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company
developing a novel delivery system for vaccines and cancer
treatments, is pleased to announce that it has engaged Melody
Janssen PhD under a consultancy contract to lead its internal and
external research program for its novel delivery system,
Nuvec(R).
Melody is an Internationally acknowledged expert in virology and
immunology and brings a wealth of experience to the Company's
research program. Melody has extensive experience of different
delivery systems and was formerly Head of R&D and pre-clinical
development for Mymetics, a leading biotech company in vaccine
development based on a proprietary virosome technology.
In conjunction with Melody's appointment, Andrew Leishman will
step down as Head of the Nuvec(R) division with effect from 10
January 2019, to enable him to take up other consultancy positions.
Thereafter, he will continue to work with and advise the Company as
a consultant.
Nigel Theobald, CEO of N4 Pharma commented:
"We are delighted to welcome Melody to the N4 team and her
wealth of experience will be invaluable to help ensure our Nuvec(R)
pharmacology program continues to provide relevant results for
potential collaborators."
Enquiries:
N4 Pharma Plc
Nigel Theobald, CEO Via Alma PR
Allenby Capital Limited Tel: +44(0)203 328 5656
James Reeve/Virginia Bull/Asha
Chotai
Alma PR
Josh Royston Tel: +44(0)778 090 1979
Robyn Fisher Tel: +44(0)754 070 6191
About N4 Pharma
N4 Pharma is a specialist pharmaceutical company developing a
novel delivery system for vaccines and cancer treatments using its
unique silica nanoparticle delivery system called Nuvec(R)
Nuvec(R) has shown to be capable of loading and delivering mRNA
and pDNA into cells to the required level needed to generate an
immune response. Further work will be undertaken for the direct
loading and delivery of peptides and proteins using Nuvec(R).
N4 Pharma's business model is to partner with companies
developing novel antigens for vaccines and cancer treatments to use
Nuvec(R) as the delivery vehicle to get their antigen into cells to
express the protein needed for the required immune response. As
these products progress through pre clinical and clinical programs
N4 will receive up front and milestone payments and ultimately
royalty payments once products reach the market.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
MSCXQLFFVFFXFBX
(END) Dow Jones Newswires
November 16, 2018 08:36 ET (13:36 GMT)
N4 Pharma (LSE:N4P)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
N4 Pharma (LSE:N4P)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024